Cargando…
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
Treatment of rheumatoid arthritis (RA) with infliximab (Remicade(®)) has been associated with the induction of antinuclear autoantibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibodies. In the present study we investigated the humoral immune response induced by infliximab against org...
Autores principales: | Ferraro-Peyret, Carole, Coury, Fabienne, Tebib, Jacques G, Bienvenu, Jacques, Fabien, Nicole |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064868/ https://www.ncbi.nlm.nih.gov/pubmed/15535831 http://dx.doi.org/10.1186/ar1440 |
Ejemplares similares
-
Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007) -
Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009) -
Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease
por: Pashnina, Irina A., et al.
Publicado: (2021) -
Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017) -
Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)